- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01123434
Immediate Postoperative Adjuvant Hormonal Treatment in High Risk Localised or Locally Advanced Prostate Cancer Patients.
January 7, 2015 updated by: AstraZeneca
A Non-interventional Study of Immediate Postoperative Adjuvant Hormonal Treatment in High Risk Localised or Locally Advanced Chinese Prostate Cancer Patients.
The primary objective is to assess the efficacy of immediate postoperative adjuvant hormonal treatment according to 2 year PSA recurrence rate in high risk localised or locally advanced Chinese prostate cancer patients.The secondary objective is to assess the quality of life(QoL)of the high risk localised or locally advanced Chinese prostate cancer patients with immediate postoperative adjuvant hormonal treatment and get the information of immediate postoperative adjuvant hormonal treatment (including the regimen, dosage and duration).
Study Overview
Status
Completed
Conditions
Study Type
Observational
Enrollment (Anticipated)
200
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Shanghai, China
- Research Site
-
Tianjin, China
- Research Site
-
-
Beijing
-
Beijing, Beijing, China
- Research Site
-
-
Guangdong
-
Guangzhou, Guangdong, China
- Research Site
-
-
Hubei
-
Wuhan, Hubei, China
- Research Site
-
-
Jiangsu
-
Nanjing, Jiangsu, China
- Research Site
-
-
Liaoning
-
Shenyang, Liaoning, China
- Research Site
-
-
Shanxi
-
Xi'an, Shanxi, China
- Research Site
-
-
Sichuan
-
Chen Du, Sichuan, China
- Research Site
-
-
Zhejiang
-
Hangzhou, Zhejiang, China
- Research Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Male
Sampling Method
Non-Probability Sample
Study Population
Patients form urology surgery
Description
Inclusion Criteria:
- Localised with one of any high recurrence risk factors(Gleason score≥8 or preoperative serum PSA≥20ng/ml), or locally advanced(T≥pT3、N0M0 and any T、N(+)M0 ) Chinese prostate cancer patients confirmed histologically through radical prostatectomy either with laparoscopy or laparotomy within 1 month after surgery. Before the patient recruitment, the investigator has decided to prescribe immediate postoperative adjuvant hormonal treatment to the patient according to the Chinese routine practice.
- Provision of written informed consent prior to any study specific procedures.
Exclusion Criteria:
- Patients must not enter the study if any of the following exclusion criteria are fulfilled
- Have used neoadjuvant hormonal treatment prior to the surgery.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
---|
1
Localised with one of any high recurrence risk factors, or locally advanced Chinese prostate cancer patients confirmed histologically through radical prostatectomy either with laparoscopy or laparotomy within 1 month after surgery.
Before the patient recruitment, the investigator has decided to prescribe immediate postoperative adjuvant hormonal treatment to the patient according to the Chinese routine practice.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To assess the efficacy of immediate postoperative adjuvant hormonal treatment according to 2 year PSA recurrence rate in high risk localised or locally advanced Chinese prostate cancer patients.
Time Frame: Up to 2 years
|
Up to 2 years
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To assess the quality of life(QoL)of the high risk localised or locally advanced Chinese prostate cancer patients with immediate postoperative adjuvant hormonal treatment.
Time Frame: Up to 2 years
|
Up to 2 years
|
Get the information of immediate postoperative adjuvant hormonal treatment (including the regimen, dosage and duration).
Time Frame: Up to 2 years
|
Up to 2 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Karen Atkin, AstraZeneca
- Study Chair: Yanjing Zhang, AstraZeneca
- Principal Investigator: Prof. Na, Peking University Shougang Hospital
- Principal Investigator: Prof. Ye, Tong Ji Hospital of Tongji Medical College of Huazhong University of Science and Technology
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
April 1, 2010
Primary Completion (Actual)
August 1, 2014
Study Completion (Actual)
August 1, 2014
Study Registration Dates
First Submitted
May 10, 2010
First Submitted That Met QC Criteria
May 12, 2010
First Posted (Estimate)
May 14, 2010
Study Record Updates
Last Update Posted (Estimate)
January 8, 2015
Last Update Submitted That Met QC Criteria
January 7, 2015
Last Verified
January 1, 2015
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- NIS-OCN-DUM-2009/2
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on 2 Years PSA Recurrence Rate
-
AstraZenecaCompletedHealthy Japanese Children Age 2 Years Through 6 YearsJapan
-
Hospices Civils de LyonCompletedLong-term Parenteral Nutrition (2 Years) in Children and AdultsFrance
-
BayerJanssen Research & Development, LLCNot yet recruitingVenous Thromboembolism | Children Under 2 YearsSpain, Sweden, Denmark, France
-
Ina-RespondNational Institute of Health Research and Development, Ministry of Health... and other collaboratorsCompletedValidation of POC-CCA Rapid Urine Test for Qualitative Detection of Schistosoma Japonicum (SchisCCA)Aged ≥2 Years in Schistosomiasis Affected AreasIndonesia
-
Assistance Publique - Hôpitaux de ParisMedian TechnologiesCompletedCT Scans Prior to Surgery With a Least 2 Years of Follow-upFrance
-
University Hospital, BrestCompletedHypoxemic Acute Respiratory Distress | Infant Between 1 Month and 24 Months Old | Child Between 2 and 15 Years OldFrance
-
Lorenzo LiviUnknownRate of PSA Response in Oligometastatic,CRPC Undergoing SBRT in Combination With Abiraterone Acetate (AA), Compared to Patients Treated With AA Alone
-
Shanghai Jiao Tong University School of MedicineCompleted
-
Sixth Affiliated Hospital, Sun Yat-sen UniversityFirst Affiliated Hospital, Sun Yat-Sen UniversityRecruitingEndoscopic Recurrence Rate | After Ileocolic Crohn 's Disease SurgeryChina
-
Abramson Cancer Center of the University of PennsylvaniaCompletedProstate Cancer Patients With Detectable PSA Following ProstatectomyUnited States